PHAXIAM Therapeutics S.A. (0QSS.L)
- GlobeNewswire
PHAXIAM provides Business and Financial Update for the First Quarter of 2024
PHAXIAM provides Business and Financial Update for the First Quarter of 2024 Webinar (in French) today, May 15, 2024, at 6.00 pm CEST Accelerated clinical efforts to roll-out PHAXIAM’s strategy in order to create a global phage-therapy leader in high-value indicationsCash and cash equivalents of €5.8 million, as of March 31, 2024 Lyon (France) and Cambridge (MA, US), May 15, 2024, at 5.45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innova
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056
- GlobeNewswire
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
The study plans for the enrolment of 12 patients in 5 French clinical centersFirst study results expected in Q3 2024This study will enable an evaluation of the intravenous administration of phages, particularly adapted to targeting indications with very high medical stakes. Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30am CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical study in endocarditis infec
